I’ve spent 11 years in pharma commercial strategy and event programming. In that time, I’ve seen teams spend tens of thousands of dollars on booth carpet, oversized swag, and "networking events" that result in nothing more than a few business cards and a hefty bar tab. If you’re a BD lead in a mid-size biotech, you don’t have the luxury of "brand visibility" for its own sake. You have medical affairs and RWE summits a portfolio to advance, licensing targets to hit, and a runway that is ticking down.
Three weeks before BIO is not the time to be finalizing your marketing brochures. It is the time for cold, hard, data-driven partnering outreach. If you are reading this while stressing about your booth location, stop. The real work is happening inside the BIO Partnering platform. If your schedule isn't locked, your strategy is failing.
Stop Choosing Conferences for the Hype—Choose Them for the Outcome
One of the biggest mistakes I see in biotech leadership is the "FOMO" conference schedule. If you are attending a conference, you should be able to articulate exactly what internal KPI that meeting is designed to influence. We don’t attend meetings to "be seen." We attend to move assets, close gaps in our competitive intelligence (CI), or solve for market access.
Here is how I classify the primary summer/fall circuit in terms of functional utility:
Conference Primary Strategic Anchor Functional Output BIO International Partnering & Licensing High-volume, time-boxed asset review and term-sheet framing. Fierce Pharma Week Commercial Execution Benchmarking go-to-market strategies and tactical CI. THMA Forums Health System Adoption Understanding formulary reality and payer pull-through.The 3-Week Countdown: Using the BIO Partnering Platform
If you aren't already deep in the BIO Partnering platform, you are already behind. At this stage, your licensing targets list should be finalized, segmented by "Hot Leads," "Strategic Fit," and "Relationship Builders."
Your goal isn't to take as many meetings as possible. It is to take the right meetings. The "meeting density" myth—the idea that a full calendar equals a successful show—is one of my biggest pet peeves. I would rather have five meetings that lead to a due diligence follow-up than 20 meetings with VCs who are just "scouting for 2026."
Your 3-Week Action Plan:
The Scrub: Review your meeting requests BIO queue. If a request doesn't align with your core therapeutic area or corporate strategy, decline it gracefully. Do not fill slots with "maybe" companies. The Narrative Refresh: Ensure every meeting lead has a one-pager that specifically addresses the partner’s pipeline gap. Do not use generic corporate decks. If you don't know what their pipeline gap is, use the next 48 hours to find out. The Internal Brief: Assign a "lead" and a "scribe" for every meeting. If you leave a meeting without a clearly defined next step (e.g., "NDAs signed by Friday"), the meeting was a failure.Beyond BIO: Commercial Execution and Formulary Reality
After BIO, the reality of commercialization hits. Many biotech teams treat licensing as the "finish line," forgetting that once the deal is signed, you still have to sell the product into a fragmented and often hostile healthcare system.
Fierce Pharma Week: The CI Engine
While BIO is for the "Big Deal," Fierce Pharma Week is where you stress-test your commercial execution. This is not for BD—this is for your marketing and strategy leads. Use this event to gather intel on how your competitors are navigating digital transformation, HCP engagement, and patient support programs. If you leave without three actionable "lessons learned" from your competitors’ recent launches, you’ve wasted your time.
The Health Management Academy (THMA): The Reality Check
If you really want to know if your drug has a chance, you need to be talking to The Health Management Academy (THMA). This is where the rubber meets the road regarding health system adoption and formulary reality.
At THMA, you aren't talking to other biotechs. You are listening to the people who decide whether your drug gets on the list. The conversations here are often uncomfortable, but they are essential. You will learn about:
- Payer hurdles you haven't accounted for. The disconnect between clinical efficacy and real-world utilization. How health systems prioritize spend during budget crunches.
If your strategy team isn't mapping your value proposition against the feedback from these forums, you are launching into a void.
The "Meetings That Do Nothing" List
I maintain a living list of meetings that look big on a calendar but do nothing for adoption. Before you commit time or resources to any event, check if it falls into one of these categories:
- The "Status Update" Coffee: A meeting with an existing partner where no new term sheet or clinical update is discussed. The "General Scout" VC Pitch: A 30-minute slot with a firm that has never invested in your space and has no intention of doing so. The "Booth Hangout": Hosting a lunch in the exhibit hall. If you want to talk to a decision-maker, get them off the floor and into a private meeting space. The noise level alone is a deal-killer.
A Note on Budget Transparency
I am frequently asked for cost comparisons for these conferences. However, conference pricing—registration fees, vendor packages, and hotel rates—fluctuates wildly based on membership tiers, corporate partnerships, and early-bird windows. Providing static numbers would be disingenuous and likely outdated by the time this post hits your feed. Focus your budget advocacy on expected ROI (e.g., number of qualified leads, competitive intelligence depth, payer insights gained) rather than the sticker price of the ticket.
Final Thoughts: Success is not an Event, it's a Milestone
The biggest disservice you can do to your team is to call a conference a "must-attend." Nothing is a must-attend if it doesn't solve a problem. In these final three weeks before BIO, strip away the noise. Forget the booth design, forget the travel logistics, and focus entirely on the quality of your partnering outreach.
Are you meeting with people who can move your asset to the next stage? Are you learning things about the market that you didn't know on Monday? If the answer THMA oncology forum 2026 registration is no, stay in the office and do the work that actually matters.